ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results

Rhea-AI Summary

ImmunoGen Inc. (Nasdaq: IMGN) announced a conference call scheduled for July 29, 2022, at 8:00 a.m. ET to discuss its Q2 2022 operating results and provide a business update. Investors can join via phone or online through their website. ImmunoGen is focused on developing advanced antibody-drug conjugates (ADCs) for cancer treatment, aiming to enhance patient outcomes and quality of life. The company emphasizes its commitment to TARGET A BETTER NOW™.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 29, 2022 to discuss its second quarter 2022 operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION

To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005101/en/

INVESTOR RELATIONS CONTACT

ImmunoGen

Anabel Chan

781-895-0600

anabel.chan@immunogen.com

MEDIA CONTACTS

ImmunoGen

Courtney O’Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen Inc.

FAQ

What is the date of ImmunoGen's upcoming conference call for Q2 2022 results?

ImmunoGen's conference call for Q2 2022 results is scheduled for July 29, 2022.

What time will ImmunoGen's Q2 2022 conference call take place?

The conference call will take place at 8:00 a.m. ET.

How can I access the ImmunoGen conference call?

You can access the call by registering online or through the Investors and Media section of ImmunoGen's website.

What is the focus of ImmunoGen's business?

ImmunoGen focuses on developing antibody-drug conjugates (ADCs) for cancer treatment.

What is ImmunoGen's commitment to cancer patients?

ImmunoGen is committed to enhancing patient outcomes through targeted therapies for cancer.